Could You Still Have Prostate Cancer After a Negative Standard (TRUS) Biopsy?

A negative prostate biopsy does not always rule out cancer. In some cases, the area of concern may not have been sampled. This article explains how standard TRUS biopsy works, why cancer can be missed, and how MRI-fusion biopsy can improve detection and guide next steps.

A negative prostate biopsy can be reassuring.

But it does not always mean that cancer is absent. In some cases, it means the area of concern was not sampled.

How Standard Biopsy Works

A standard TRUS biopsy takes multiple tissue samples from different areas of the prostate using a systematic pattern. These samples are not guided by visible targets but are taken at regular intervals throughout the gland. This approach has been widely used for many years, but it has its limitations.

Why Cancer Can Be Missed

Systematic biopsy may miss clinically significant cancer, particularly when lesions are located in areas that are harder to reach.

This includes:

  • top of the prostate (farthest away from the rectum)
  • smaller or early-stage lesions
  • areas outside the standard sampling zones

In these situations, a biopsy may return negative even when a lesion is present.

The Role of MRI

Prostate MRI has changed how these situations are evaluated. It can identify suspicious areas that are not captured by standard biopsy, assigning a PI-RADS (Prostate Imaging Reporting and Data Systems) score to calculate the likelihood of finding clinically significant cancer. When MRI identifies a lesion, the next step is often a targeted MRI-fusion biopsy.

What MRI-Fusion Biopsy Adds

MRI-fusion biopsy combines MRI imaging with real-time ultrasound guidance.

This allows the physician to:

  • target specific lesions seen on MRI
  • sample areas that were previously missed
  • improve detection of clinically significant disease

This approach is particularly useful when:

Prostate Cancer Treatment Options

Learn about advanced, minimally invasive therapies available at UIC Toronto.
Discuss Your Options
  • PSA continues to rise
  • MRI shows a suspicious lesion
  • In men with larger prostates, a standard TRUS biopsy may not adequately sample the entire gland

What This Means for Focal Therapy

Focal treatment depends on accurate lesion identification.

A previous negative biopsy does not automatically rule out focal therapy.
In many cases, a targeted biopsy confirms localized disease that can be treated precisely.

The key is ensuring that the cancer has been fully and accurately mapped before making a treatment decision.

Moving Forward After Uncertainty

A negative biopsy followed by ongoing concern can be frustrating.

MRI and targeted biopsy provide a way to move forward with greater clarity.

Book a consultation with Urology Innovations Canada to review whether an  MRI fusion biopsy is appropriate in your case.

Share this
UIC logo
Location

123 Edward Street, Suite 1401
Toronto, Ontario M5G 1E2 Canada
Fax: +1 (416) 979-9002

Urology Innovations Canada (UIC) is a leading provider of advanced, minimally invasive treatments for prostate cancer, BPH, and other urological conditions. As the first clinic in downtown Toronto to offer NanoKnife (IRE) and one of the most experienced HIFU providers in North America, we specialize in precision focal therapies that prioritize effectiveness while preserving quality of life. Our expert team serves patients from Toronto, the Greater Toronto Area, across Canada, and internationally.

The reviews and testimonials featured on this website represent the individual experiences of our patients. Results may vary from person to person, and no outcome is guaranteed. These reviews are intended to provide insight into the experiences of others and should not be used as a substitute for professional medical advice. Please book a consultation with one of our Toronto urologists to determine the best course of treatment for your unique needs.

© 2026 Urology Innovations Canada. All rights reserved.